- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Syneron, Candela announce merger finalization
Wayland, Mass. - Officials of aesthetic-device makers Syneron Medical of Israel and Candela, based here, have announced the successful closing of their merger, according to PR-inside.com.
Wayland, Mass.
- Officials of aesthetic-device makers Syneron Medical of Israel and Candela, based here, have announced the successful closing of their merger, according to PR-inside.com.
The official closing follows a special meeting on Jan. 5, during which Candela shareholders voted in favor of the proposed merger agreement. The proposal previously had won unanimous approval by both companies’ boards of directors.
Under terms of the agreement, Syneron will maintain its corporate headquarters in Israel and North American office in Irvine, Calif. Candela will continue to operate as a wholly owned Syneron subsidiary and will maintain its main office in Wayland and subsidiary operations in Australia, France, Germany, Italy, Japan, Portugal, Spain and the United Kingdom.
